AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02178163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytology specimen collection procedure
Description: Correlative studies
Study NCT02178163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02284022 — intervention group
Intervention type: DEVICE
Intervention: Brain computer interface
Description: Recording the P300 Testing the device Using the device with a speller
Study NCT01244204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Daily dose of 800IU of vitamin D
Study NCT01244204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing capsules
Study NCT04242459 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning
Study NCT01946659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence to Sleep Apnea Treatment
Description: A health education material prepared after focus group discussion with community leaders and patients would be administered to the participants with an experienced health educator through phone. Upto 10 calls per each patient will be made to either group until 6 months or the patient has a sleep test done.
Study NCT01946659 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care Group
Description: The standard care group gets a standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine
Study NCT01316458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI571 (Glivec®)
Study NCT04633135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips stove
Description: Philips Smokeless stove HD4012LS
Study NCT04633135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gyapa stove
Description: Wood stove made in Ghana
Study NCT03926910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection of hypovolemia using a ventricular stimulation without atrial pacing
Description: Upon the return in intensive care:~* Baseline measurements: 1) Three measurements of blood pressure during inspiration and 3 during expiration will be collected for averaging systolic blood pressure, diastolic blood pressure, mean arterial pressure and ΔPP. Data from a pulmonary artery catheter will be also collected.~* Realization of VESAP pacing with adjustment of the pacemaker (PM) at a heart rate 5 bpm higher than the heart rate of the patient. After 20 seconds of stimulation, recording of the blood pressure curve as done at baseline during at least 3 respiratory cycles,~* Then vascular filling with 500 ml of physiologic saline solution over 10 minutes and new set of measurement (same than at baseline)~* Second realization of VESAP pacing, and new set of measurement (same than at Baseline)~* Then, if the ΔPP is >10%, new vascular filling with 500 ml of physiologic saline solution over 10 min and new set of measurements as previously performed.
Study NCT04463537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Body Temperature Measurements
Description: measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form.
Study NCT01053507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan/naproxen sodium
Description: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
Study NCT01053507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
Study NCT03804242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black Youth M.A.T.T.E.R.: Molding Young Advocates While Transforming the School to Prison Pipeline Through Psychological Services Education and Resilience
Description: This is a group psychoeducational and positive youth development intervention for students who have been expelled from school and are now enrolled in a specialized school at Youth Justice Coalition.
Study NCT02703142 — intervention group
Intervention type: PROCEDURE
Intervention: Patients after esophagectomy
Description: postoperative endoscopic evaluation
Study NCT01101893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: raltegravir 400mg q12h x 5 days (Reference Treatment)
Study NCT01101893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: GSK2248761 200mg q24h x 5 days (Reference Treatment)
Study NCT01101893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 + Raltegravir
Description: GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)
Study NCT03118505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infuse Bone Graft
Description: Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation
Study NCT03118505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic DBM
Description: Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
Study NCT03976050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: HL-085 is a MEK inhibitor with potential indication for cancers. it will be given twice daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative anti-tumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
Study NCT02692963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Description: BCG vaccine InterVax
Study NCT02991534 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CV Toolkit Components
Description: * Patient completes a CV self screener.~* Patient discusses CV risks factors with primary care providers and CV risks are documented and discussed for action steps and referrals.~* Patient will be recommended to attend a gender tailored facilitated workgroup - Gateways to Healthy Living to make specific SMART goals and commit to patient preferred services or program
Study NCT00610649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8777
Description: Orally administered capsules containing either 50 mg or 100 mg MK-8777.
Study NCT04116216 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: High frequency repetitive transcranial magnetic stimulation
Description: The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
Study NCT04116216 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency repetitive transcranial magnetic stimulation
Description: The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
Study NCT02785783 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy
Study NCT02785783 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoRings™
Description: Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
Study NCT02253082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OctaplasLG®
Description: OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
Study NCT04116216 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
Study NCT01153893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, 1 or 2 doses
Study NCT01153893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: InfanrixTM
Description: Intramuscular injection, 1dose
Study NCT04362813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab 450 mg for body weight 40-\<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
Study NCT04362813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
Study NCT03621306 — intervention group
Intervention type: DEVICE
Intervention: DXA and pQCT precision testing
Description: The participants are only being observed; there is no intervention other than DXA and pQCT testing for the purposes of looking at instrument/technician precision..
Study NCT02253082 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fresh frozen plasma
Description: Standard FFP from the Blood Bank
Study NCT03990532 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: treatment group(phase I)
Description: Dose-escalation plan (phase I)~Radiotherapy:~LEVEL 1: dose given at PTV-G will be 58.8Gy/28 fractions； 2.1Gy/per fraction; LEVEL 2: dose given at PTV-G will be 64.4Gy/28 fractions； 2.3Gy/per fraction; LEVEL 3: dose given at PTV-G will be 70Gy/28 fractions； 2.5Gy/per fraction Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
Study NCT03990532 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: treatment group (phase II)
Description: Radiotherapy dose was prescribed according to phase I trial results; Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
Study NCT04858841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam Oral Product
Description: Administer levetiracetam powder once a day in eligible patients
Study NCT04858841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel Oral Product
Description: Administer perampanel powder once a day in eligible patients
Study NCT04858841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer placebo powder once a day in eligible patients
Study NCT02882191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LevoCept
Description: placement of LevoCept IUD
Study NCT00463086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
Study NCT00463086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
Study NCT01206140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01206140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study NCT01206140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT02147509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.02% Fm, SH
Description: Sjogren's Syndrome patients with severe dry eye
Study NCT02147509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.02% Fm, SH, 0.05% CsA
Description: Sjogren's Syndrome patients with severe dry eye
Study NCT01887964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RS4 enriched flour
Description: Wheat flour with 30% resistant starch (type-4)
Study NCT01887964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control flour
Description: Wheat flour without resistant starch (type-4)
Study NCT03497468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined exercise training
Description: Aerobic training with cycle ergometer %60-80 of maximal Heart Rate, submaximal level, strengthening of the major muscles of upper and lower extremities
Study NCT03497468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented training
Description: Functional reaching, walking on different obstacles and floor,sitting and standing on different levels and surface,walking around obstacle, climbing stairs with different height and surface
Study NCT02562846 — intervention group
Intervention type: OTHER
Intervention: Psychological testing and biological sample collection
Description: For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
Study NCT01803880 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Debridement
Description: mechanical shaver that removes areas of damaged tissue
Study NCT01803880 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RF-Based Debridement
Description: Electrical energy that removes areas of damaged tissue (Coblation®)
Study NCT03133494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ABG analysis
Description: ABG analysis was performed and compared between two groups
Study NCT03133494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ABG analysis
Description: ABG analysis was performed and compared between two groups
Study NCT04535973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: unstimulated saliva sample for hormone analysis
Description: hormone levels will be determined in frozen samples of unstimulated saliva
Study NCT04535973 — intervention group
Intervention type: OTHER
Intervention: quality of life questionnaire
Description: all participants will fill out self-perceived quality of life questionnaire
Study NCT02508363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Study NCT02508363 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Study NCT02509936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based nutrition education
Description: Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
Study NCT02509936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard-of-care nutrition support
Description: Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
Study NCT02509936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care nutrition support
Description: Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
Study NCT01143961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSC100 - Verso airway access adapter CareFusion
Description: Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
Study NCT01127984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tissucol
Description: dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
Study NCT01127984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: drainage system
Description: application of vacuum drainage system
Study NCT04295837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABLE
Description: Home-based occupational therapy compensatory programme addressing activities of daily living
Study NCT04295837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard occupational therapy
Study NCT01094834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP05195
Description: tablets, oral administration, multiple administration
Study NCT02236572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~* Anastrozole 1 mg~* Letrozole 2.5 mg~* Exemestane 25 mg
Study NCT01487486 — intervention group
Intervention type: DRUG
Intervention: IVF Antagonist Protocol
Description: 1. Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.~2. Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle >14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection~3. hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval.
Study NCT02147509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.02% Fm, SH, tBCL
Description: Sjogren's Syndrome patients with severe dry eye
Study NCT02147509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.02% Fm, SH, AS
Description: Sjogren's Syndrome patients with severe dry eye
Study NCT01488409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: 250 mg by mouth (PO) three times daily
Study NCT01488409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg by mouth (PO) three times daily
Study NCT02023268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T2762
Description: 1 drop in each eye 3 to 6 times daily during 84 days
Study NCT02023268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vismed®
Description: 1 drop in each eye 3 to 6 times daily during 84 days
Study NCT03163108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop automatic oxygen control (CLAC) fast in addition to RMC
Description: Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 30s).
Study NCT03163108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop automatic oxygen control (CLAC) slow in addition to RMC
Description: Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 180s).
Study NCT02197520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Administered subcutaneously (SC), (U-100 formulation)
Study NCT02197520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered subcutaneously (SC), (U-100 formulation)
Study NCT02197520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC), (U-100 formulation)
Study NCT02197520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC), (U-100 formulation)
Study NCT02402114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: 120 mg Hydrocortisone given orally one time.